Opdivo Turned Down By NICE In Head And Neck Cancer
Executive Summary
BMS looks unlikely to have a positive NICE opinion synchronized with European approval of Opdivo in head and neck cancer, after the HTA body turned down the checkpoint inhibitor in its draft appraisal.
You may also be interested in...
NICE Rejects BMS' Opdivo As Adult Kidney Cancer Treatment
The UK HTA NICE in draft guidance has rejected Bristol-Myers Squibb Co.'s Opdivo (nivolumab) as a therapy for previously treated advanced renal cell carcinoma in adults, saying the PD-1 inhibitor doesn't offer value for money. It added that it should also not be made available to such patients through the government-funded Cancer Drugs Fund, for the same reasons.
UK's NICE OKs BMS' Opdivo-Yervoy Combo In Advanced Skin Cancer
The UK HTA has recommended Bristol-Myers Squibb's combination therapy of Opdivo and Yervoy to treat patients on the publicly-funded NHS with advanced skin cancer, marking one of the quickest decisions ever from NICE and issued only weeks after the combo was licensed by the EU's European Commission.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.